STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot

Zacks2024-12-16

Stereotaxis, Inc. STXS and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration (“NMPA”) for the Magbot Magnetic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492612882?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41","is_english":true,"pubTime":"2024-12-16 23:58","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492612882","market":"us","top_or_hot":-1,"title":"STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot","media":"Zacks","content":"<div>\n<p>Stereotaxis, Inc. STXS and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration (“NMPA”) for the Magbot Magnetic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/stxs-stock-post-nmpa-nod-155800389.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSTXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-16 23:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/stxs-stock-post-nmpa-nod-155800389.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stereotaxis, Inc. STXS and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration (“NMPA”) for the Magbot Magnetic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/stxs-stock-post-nmpa-nod-155800389.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0792757196.USD","symbol_name":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/stxs-stock-post-nmpa-nod-155800389.html","article_id":"2492612882","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492612882","pubTimestamp":1734364680,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Stereotaxis, Inc. STXS and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration  for the Magbot Magnetic Navigation Ablation Catheter last Monday. Stereotaxis had previously announced its collaboration with MicroPort EP in August 2021.It is worthwhile to note that the Magbot Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in conjunction with Stereotaxis’ robotic systems, including the recently NMPA-approved Genesis RMN and MicroPort EP’s Columbus 3D EP Mapping System.MicroPort EP will initiate commercial launch of Magbot in China through its existing sales team focused on the electrophysiology community, while Stereotaxis will also benefit from the proceeds from Magbot adoption.The latest regulatory clearance is a significant stepping stone for Stereotaxis to","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4082":"医疗保健设备","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0566484027.USD":"安本美国小盘成长股","BK4588":"碎股","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4198":"医疗保健用品","POST":"Post Holdings","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","CSII":"Cardiovascular Systems","MMSI":"Merit Medical Systems","LMAT":"勒梅特微管医疗","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4175":"保健护理产品经销商","BK4212":"包装食品与肉类","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","STXS":"趋实医疗设备","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","BK4585":"ETF&股票定投概念","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","CAH":"卡地纳健康","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC"},"translate_title":"STXS在NMPA批准使用Magbot进行心血管护理后储备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STXS":1,"POST":1,"MMSI":1,"CAH":1,"CSII":1,"LMAT":1},"content_text":"Stereotaxis, Inc. STXS and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration (“NMPA”) for the Magbot Magnetic Navigation Ablation Catheter last Monday. Stereotaxis had previously announced its collaboration with MicroPort EP in August 2021.\nIt is worthwhile to note that the Magbot Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in conjunction with Stereotaxis’ robotic systems, including the recently NMPA-approved Genesis RMN and MicroPort EP’s Columbus 3D EP Mapping System.\nMicroPort EP will initiate commercial launch of Magbot in China through its existing sales team focused on the electrophysiology community, while Stereotaxis will also benefit from the proceeds from Magbot adoption.\nThe latest regulatory clearance is a significant stepping stone for Stereotaxis to strengthen its foothold in the global cardiovascular care space.\nLikely Trend of STXS Stock Following the News\nFollowing the announcement on Dec. 9, shares of the company gained nearly 5.9% till Friday’s trading.\nHistorically, the company has gained a topline boost from its various regulatory clearances. We expect market sentiment on the stock to continue to remain positive around this announcement, too.\nStereotaxis currently has a market capitalization of $198.3 million. Its current cash flow growth of 13.4% is favorable against the industry’s negative growth. In the last reported quarter, STXS delivered a negative earnings surprise of 60%.\nSignificance of Stereotaxis’ NMPA Approval\nAccording to Stereotaxis’ management, Magbot incorporates advanced design features that are expected to enhance the efficiency, effectiveness and safety of robotic magnetic catheter ablation. Robotically navigated using low-intensity magnetic fields, the Magbot catheter will likely be able to reach areas of the heart that are otherwise difficult to access with traditional methods and to maintain precise positioning and stability on cardiac anatomy with high accuracy.\nPer MicroPort EP’s management, the approval of the Magbot Catheter signifies a major breakthrough for MicroPort EP in cardiac electrophysiology and a significant milestone for robotic navigation technology in China. Its recent technological advances with Stereotaxis are expected to offer a safer and more precise minimally-invasive treatment solution for complex arrhythmia patients.\nIndustry Prospects in Favor of STXS\nPer a report by Grand View Research, the global cardiovascular devices market is valued at $53.67 billion in 2024 and is projected to witness a CAGR of 8.4% between 2025 and 2030. Factors like increasing cardiovascular disorders, an increase in the availability of affordable and effective devices, and rising demand for minimally-invasive procedures are likely to drive the market.\nGiven the market potential, the latest regulatory clearance is expected to provide a significant boost to Stereotaxis’ business.\nStereotaxis’ Notable Developments\nLast month, Stereotaxis, along with MicroPort EP, received China’s NMPA approval for the Genesis Robotic Magnetic Navigation (RMN) System.\nThe same month, Stereotaxis announced that physicians at the Hospital da Luz in Lisbon, Portugal, had successfully treated the first patients using the advanced Genesis RMN System.\nSTXS’s Share Price Performance\nShares of the company have gained 45.4% in the past year compared with the industry’s 7.7% rise and the S&P 500's 28.6% growth.\nImage Source: Zacks Investment Research\nStereotaxis’ Zacks Rank & Key Picks\nCurrently, STXS carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Cardinal Health, Inc. CAH, Merit Medical Systems, Inc. MMSI and LeMaitre Vascular, Inc. LMAT.\nCardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nCardinal Health’s shares have gained 16.1% compared with the industry’s 4.9% rise in the past year.\nMerit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.4%.\nMerit Medical has gained 44.6% compared with the industry’s 4.9% rise in the past year.\nLeMaitre Vascular, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.1%.\nLeMaitre Vascular’s shares have rallied 68.2% compared with the industry’s 13.9% rise in the past year.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nMerit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report\nStereotaxis Inc. (STXS) : Free Stock Analysis Report\nLeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492612882"}